These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Localization and distribution of tissue type and urokinase type plasminogen activators and their inhibitors Type 1 and 2 in human and rhesus monkey fetal membranes. Liu YX; Hu ZY; Liu K; Byrne S; Zou RJ; Ny T; d'Lacey C; Ockleford CD Placenta; 1998; 19(2-3):171-80. PubMed ID: 9548184 [TBL] [Abstract][Full Text] [Related]
44. The intermediate filament protein, vimentin, in the lens is a target for cross-linking by transglutaminase. Clément S; Velasco PT; Murthy SN; Wilson JH; Lukas TJ; Goldman RD; Lorand L J Biol Chem; 1998 Mar; 273(13):7604-9. PubMed ID: 9516464 [TBL] [Abstract][Full Text] [Related]
45. A novel form of the plasminogen activator inhibitor created by cysteine mutations extends its half-life: relevance to cancer and angiogenesis. Chorostowska-Wynimko J; Swiercz R; Skrzypczak-Jankun E; Wojtowicz A; Selman SH; Jankun J Mol Cancer Ther; 2003 Jan; 2(1):19-28. PubMed ID: 12533669 [TBL] [Abstract][Full Text] [Related]
46. Biochemical, structural, and transglutaminase substrate properties of human loricrin, the major epidermal cornified cell envelope protein. Candi E; Melino G; Mei G; Tarcsa E; Chung SI; Marekov LN; Steinert PM J Biol Chem; 1995 Nov; 270(44):26382-90. PubMed ID: 7592852 [TBL] [Abstract][Full Text] [Related]
47. Selective modification by transglutaminase of a glutamine side chain in the hinge region of the histidine-388----glutamine mutant of yeast phosphoglycerate kinase. Coussons PJ; Kelly SM; Price NC; Johnson CM; Smith B; Sawyer L Biochem J; 1991 Jan; 273(Pt 1)(Pt 1):73-8. PubMed ID: 1671205 [TBL] [Abstract][Full Text] [Related]
48. Identification of a substrate site for liver transglutaminase on the aminopropeptide of type III collagen. Bowness JM; Folk JE; Timpl R J Biol Chem; 1987 Jan; 262(3):1022-4. PubMed ID: 2879837 [TBL] [Abstract][Full Text] [Related]
49. Transglutaminase-catalyzed cross-linking of fibrils of collagen V/XI in A204 rhabdomyosarcoma cells. Kleman JP; Aeschlimann D; Paulsson M; van der Rest M Biochemistry; 1995 Oct; 34(42):13768-75. PubMed ID: 7577969 [TBL] [Abstract][Full Text] [Related]
50. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop. Audenaert AM; Knockaert I; Collen D; Declerck PJ J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724 [TBL] [Abstract][Full Text] [Related]
52. Assays for the measurement of tissue transglutaminase (type II) mediated protein crosslinking via epsilon-(gamma-glutamyl) lysine and N',N'-bis (gamma-glutamyl) polyamine linkages using biotin labelled casein. Lilley GR; Griffin M; Bonner PL J Biochem Biophys Methods; 1997 Feb; 34(1):31-43. PubMed ID: 9089382 [TBL] [Abstract][Full Text] [Related]
53. Substrate behavior of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop. Gils A; Knockaert I; Declerck PJ Biochemistry; 1996 Jun; 35(23):7474-81. PubMed ID: 8652525 [TBL] [Abstract][Full Text] [Related]
54. Substrate specificity analysis of microbial transglutaminase using proteinaceous protease inhibitors as natural model substrates. Taguchi S; Nishihama KI; Igi K; Ito K; Taira H; Motoki M; Momose H J Biochem; 2000 Sep; 128(3):415-25. PubMed ID: 10965040 [TBL] [Abstract][Full Text] [Related]
55. Conformational changes of the reactive-centre loop and beta-strand 5A accompany temperature-dependent inhibitor-substrate transition of plasminogen-activator inhibitor 1. Kjøller L; Martensen PM; Sottrup-Jensen L; Justesen J; Rodenburg KW; Andreasen PA Eur J Biochem; 1996 Oct; 241(1):38-46. PubMed ID: 8898886 [TBL] [Abstract][Full Text] [Related]
56. Dimerization of midkine by tissue transglutaminase and its functional implication. Kojima S; Inui T; Muramatsu H; Suzuki Y; Kadomatsu K; Yoshizawa M; Hirose S; Kimura T; Sakakibara S; Muramatsu T J Biol Chem; 1997 Apr; 272(14):9410-6. PubMed ID: 9083079 [TBL] [Abstract][Full Text] [Related]
57. Reversible interactions between plasminogen activators and plasminogen activator inhibitor-1. Mimuro J; Kaneko M; Murakami T; Matsuda M; Sakata Y Biochim Biophys Acta; 1992 Dec; 1160(3):325-34. PubMed ID: 1477106 [TBL] [Abstract][Full Text] [Related]
58. Substance P as a transglutaminase substrate: identification of the reaction products by fast atom bombardment mass spectrometry. Porta R; Esposito C; Metafora S; Pucci P; Malorni A; Marino G Anal Biochem; 1988 Aug; 172(2):499-503. PubMed ID: 2461117 [TBL] [Abstract][Full Text] [Related]
59. Addressing substrate glutamine requirements for tissue transglutaminase using substance P analogues. Pastor MT; Diez A; Pérez-Payá E; Abad C FEBS Lett; 1999 May; 451(3):231-4. PubMed ID: 10371195 [TBL] [Abstract][Full Text] [Related]
60. Plasminogen activator inhibitor-2 is highly tolerant to P8 residue substitution--implications for serpin mechanistic model and prediction of nsSNP activities. Di Giusto DA; Sutherland AP; Jankova L; Harrop SJ; Curmi PM; King GC J Mol Biol; 2005 Nov; 353(5):1069-80. PubMed ID: 16214170 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]